Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation

Wallentin, LarsLopes, Renato D.Hanna, MichaelThomas, LaineHellkamp, AnneNepal, SunilHylek, ElaineAl-Khatib, Sana M.Alexander, John H.Alings, MarcoAmerena, JohnAnsell, JackAylward, PhilipBartunek, JozefCommerford, PatrickDe Caterina, RaffaeleErol, ÇetinHarjola, Veli-PekkaHeld, ClaesHorowitz, JohnHuber, KurtHusted, SteenKeltai, MatyasLanas, FernandoLisheng, LiuMcMurray, JohnOh, Byung HeeRosenqvist, MårtenRuzyllo, WitoldSteg, Philippe GabrielVinereanu, DragosXavier, DenisGranger, Christopher B.2025-10-1720130009-732210.1161/CIRCULATIONAHA.112.142158https://hdl.handle.net/20.500.14802/31814In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).anticoagulationapixabanatrial fibrillationbleedingstrokewarfarinEfficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillationJournal article2-s2.0-84878535107Open accessControlled201046016